Process of making somatostatin modulators

Inventors

REDDY, Jayachandra P. • Mirmehrabi, Mahmoud

Assignees

Crinetics Pharmaceuticals Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-10889561-B2

Patent

Publication Date

2021-01-12

Expiration Date


Abstract

Described herein are compounds that are somatostatin modulators, methods of making such compounds, pharmaceutical compositions and medicaments comprising such compounds, and methods of using such compounds in the treatment of conditions, diseases, or disorders that would benefit from modulation of somatostatin activity.

Core Innovation

The patent disclosure describes crystalline 3-[4-(4-amino-piperidin-1-yl)-3-(3,5-difluoro-phenyl)-quinolin-6-yl]-2-hydroxy-benzonitrile monohydrochloride, also designated Compound A mono-HCl, or a solvate thereof, characterized by XRPD, DSC, and IR spectral properties. The text reports SSTR2 agonist and modulator activity for the compound, alongside comparisons of solubility and moisture uptake among salt forms. It also describes preparation routes and purification for quinoline analogs, reporting improvements in HPLC purity and measures addressing residual palladium.

The independent claim covers orally administering a pharmaceutical composition comprising the crystalline monohydrochloride compound or a solvate thereof and at least one pharmaceutically acceptable excipient to a human with acromegaly, a neuroendocrine tumor, or both. The crystalline compound further exhibits an unchanged XRPD pattern following exposure to heat and humidity. The compound is identified for potential therapeutic use in treating acromegaly and neuroendocrine tumors.

Claims Coverage

The claims identify one independent claim directed to oral treatment using a pharmaceutical composition containing the specified crystalline monohydrochloride compound or a solvate thereof, comprising two inventive features.

Oral treatment of acromegaly or a neuroendocrine tumor

The claim covers orally administering to a human with acromegaly, a neuroendocrine tumor, or both, a pharmaceutical composition comprising the specified crystalline monohydrochloride compound or a solvate thereof and at least one pharmaceutically acceptable excipient, with dependent claims specifying amounts of 1-100 mg, once-daily administration, and tablet or capsule forms.

Characterized crystalline form of the monohydrochloride compound

The crystalline compound is characterized by an XRPD pattern with peaks at 4.5°, 9.1°, 10.2°, 16.3°, 18.4°, and 19.1° 2-Theta; a DSC endotherm with an onset at about 207°C and a peak at about 220°C; and IR peaks at 2223, 1620, 1595, 1457, 1238, 1220, and 1117 cm⁻¹, with an unchanged XRPD pattern after heat or humidity exposure.

The independent claim combines oral treatment of acromegaly, a neuroendocrine tumor, or both in a human with a pharmaceutical composition containing the crystalline monohydrochloride form defined by XRPD, DSC, and IR parameters and stability under heat or humidity exposure.

Stated Advantages

The crystalline monohydrochloride salt remains crystalline after heating to 200°C and maintains an unchanged XRPD pattern under heat and high-humidity exposure.

The monohydrochloride salt shows lower reversible moisture uptake than the dihydrochloride salt.

Documented Applications

Oral treatment in humans of acromegaly, a neuroendocrine tumor, or both, using a pharmaceutical composition containing the crystalline monohydrochloride compound or a solvate thereof.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.